Medigene AG (ETR:MDG1 – Get Free Report) shares rose 4.8% on Wednesday . The stock traded as high as €1.55 ($1.67) and last traded at €1.54 ($1.66). Approximately 37,361 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 306,207 shares. The stock had previously closed at €1.47 ($1.58).
Medigene Stock Up 4.8 %
The firm has a market capitalization of $39.84 million, a P/E ratio of -2.44, a PEG ratio of 7.12 and a beta of 0.85. The company has a debt-to-equity ratio of 14.00, a quick ratio of 5.85 and a current ratio of 2.53. The stock has a 50 day moving average of €1.79 and a 200-day moving average of €1.62.
Medigene Company Profile
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Recommended Stories
- Five stocks we like better than Medigene
- What is Short Interest? How to Use It
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- With Risk Tolerance, One Size Does Not Fit All
- Generac Powers Ahead on the Electrification Mega-Trend
- What does consumer price index measure?
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
